Gujarat Themis Biosyn Ltd
Gujarat Themis Biosyn: Q2 FY27 Consolidated Net Loss INR (1,384.33) Lakhs
RESULTS
▼ Concern Flagged
HIGH RISK
📅 Filed on BSE: 14 Nov 2026, 04:13 PM IST · BSE ID: 900a5397-b0ad-46dc-8246-d54befb0c8f3
View Original BSE Filing (PDF)
💡
In Simple Terms
The company reported a financial loss in the last quarter, acquired a new subsidiary, and its Company Secretary resigned.
🤖 AI Summary
- Consolidated net loss for Q2 FY27 was INR (1,384.33) Lakhs, with total income of INR 5,372.30 Lakhs.
- The Board approved unaudited standalone and consolidated financial results for Q2 FY27.
- Mr. Vineet Gawankar resigned as Company Secretary, effective November 30, 2026.
- Financial results are not comparable to prior periods due to subsidiary acquisition on September 18, 2026.
- Paid-up equity share capital increased to INR 1,301.52 Lakhs following a QIP on August 28, 2026.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Consolidated Net Profit/(Loss) after tax Q2 FY27
(1,384.33) INR Lakhs
Not comparable — limited prior period data.
Consolidated Total Income Q2 FY27
5,372.30 INR Lakhs
Not comparable — limited prior period data.
Consolidated Net Profit/(Loss) after tax H1 FY27
(277.66) INR Lakhs
Not comparable — limited prior period data.
Consolidated Total Income H1 FY27
9,764.47 INR Lakhs
Not comparable — limited prior period data.
Paid-up equity share capital as at September 30, 2026
1,301.52 INR Lakhs
Goodwill as at September 30, 2026 (restated)
1061.45 INR Crore
🏢 How This Affects the Company
The acquisition of MicroBiopharm Japan Co. Ltd. on September 18, 2026, impacts the group's operational footprint by including its results from the acquisition date. The group's focus remains on manufacturing fermentation-based pharmaceutical intermediates and APIs.
The consolidated net loss of INR (1,384.33) Lakhs for Q2 FY27 reflects the impact of the recent acquisition and a significant increase in finance costs. The Qualified Institutions Placement (QIP) raised INR 750 crore, increasing paid-up equity share capital to INR 1,301.52 Lakhs.
The inclusion of MicroBiopharm Japan Co. Ltd. (MBJ) results from September 18, 2026, integrates a new entity into the group's operations. The reported exceptional items include a loss incurred in MBJ due to an earthquake.
The financial results are not comparable to previous periods due to the acquisition, introducing complexity in trend analysis. Provisional accounting for the acquisition, including goodwill of JPY 1735.52 Crore (restated at INR 1061.45 Crore), presents a risk of future adjustments based on final Purchase Price Allocation.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this filing.
👤
Who Is Affected
Shareholders are affected by the consolidated net loss reported for Q2 FY27 and the change in the company's capital structure due to the Qualified Institutions Placement, which increased paid-up equity share capital to INR 1,301.52 Lakhs.
🔍
Management Signal
The Board's approval of the acquisition and QIP indicates a strategic focus on inorganic growth and expansion, while the provisional nature of acquisition accounting suggests ongoing financial and operational integration work.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List - track these upcoming events
Q3 FY27 financial results — monitor consolidated performance post-acquisition.
Final Purchase Price Allocation for MBJ acquisition — confirm goodwill amount.
Appointment of new Company Secretary — observe leadership changes.
HIGH RISK
The reported net loss, significant increase in finance costs, and the provisional nature of acquisition accounting introduce financial and operational uncertainties.
💡 Investor Takeaway
Gujarat Themis Biosyn reported a consolidated net loss of INR (1,384.33) Lakhs for Q2 FY27. Total income was INR 5,372.30 Lakhs. The QIP raised INR 750 crore, and a subsidiary was acquired, making current results incomparable to prior periods.
⚖️ Strengths & Concerns
✅ Positives
- Successful Qualified Institutions Placement (QIP) on August 28, 2026, raised INR 750 crore for inorganic growth and general corporate purposes.
- Acquisition of 100% shares of MicroBiopharm Japan Co. Ltd. (MBJ) through subsidiary TBJ on September 18, 2026, expands the group's structure.
⚠️ Concerns
- Consolidated net loss for Q2 FY27 was INR (1,384.33) Lakhs, a decline from a net profit of INR 1,426.40 Lakhs in Q2 FY26.
- Finance Costs increased significantly to INR 835.50 Lakhs in Q2 FY27 compared to INR 4.04 Lakhs in Q2 FY26.
📅 Company Track Record
Gujarat Themis Biosyn Ltd. had previously informed BSE about a board meeting on August 7, 2026, to approve its Q1 FY27 financial results. The company's Q2 FY27 results follow significant corporate actions including a Qualified Institutions Placement and a subsidiary acquisition.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What were Gujarat Themis Biosyn's consolidated net results for Q2 FY27?
Gujarat Themis Biosyn reported a consolidated net loss after tax of INR (1,384.33) Lakhs for the quarter ended September 30, 2026 (Q2 FY27).
What was the total consolidated income for Gujarat Themis Biosyn in Q2 FY27?
The total consolidated income for Gujarat Themis Biosyn in Q2 FY27 was INR 5,372.30 Lakhs.
Why are Gujarat Themis Biosyn's Q2 FY27 results not comparable to previous periods?
The Q2 FY27 consolidated financial results are not comparable to corresponding previous periods due to the acquisition of 100% shares of MicroBiopharm Japan Co. Ltd. (MBJ) on September 18, 2026, whose results are included from the acquisition date.
What was the impact of the Qualified Institutions Placement (QIP) on Gujarat Themis Biosyn's equity?
During Q2 FY27, the company allotted 2,11,86,440 equity shares via QIP, aggregating to INR 750 crore. This increased the paid-up equity share capital from INR 1,089.65 Lakhs to INR 1,301.52 Lakhs.
Who resigned from Gujarat Themis Biosyn, and when is it effective?
Mr. Vineet Gawankar resigned from the position of Company Secretary and Compliance Officer of Gujarat Themis Biosyn Limited, effective from November 30, 2026.
Questions based on this BSE filing only. For information purposes.